how her2+breast cancer subtypes differ(and why some respond better2 targeted therapy
 

I have previously commended Maurizio Scaltriti, who did the original preclinical research showing the supersynergism of herceptin plus lapatinib --the basis for the neoadjuvant studies and for the combined treatment many of you have benefitted from


http://www.readcube.com/articles/10....4269?locale=en

Re: how her2+breast cancer subtypes differ(and why some respond better2 targeted ther
 

Lani I had trouble reading this, would you mind condensing it for me please??

Re: how her2+breast cancer subtypes differ(and why some respond better2 targeted ther
 

I had a similar problem, after the abstract the pages were blurred. I'm sure the information is fascinating. I second Tricia's request.

Re: how her2+breast cancer subtypes differ(and why some respond better2 targeted ther
 

My iPad wouldn't open this article, but I would like a analogy I am sure....I think Lani should just write a page and then list the article for super science genius people to read if they like!��